Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2011

01-09-2011 | Original Article

18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study

Authors: Sheng-Chieh Chan, Hung-Ming Wang, Tzu-Chen Yen, Chien-Yu Lin, Shy-Chyi Chin, Chun-Ta Liao, Yau-Yau Wai, Jiun-Jie Wang, Shu-Hang Ng

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2011

Login to get access

Abstract

Purpose

The aim of this prospective study was to compare the diagnostic value of 18F-FDG PET/CT and 3.0-T whole-body MRI (WB-MRI) for the assessment of distant metastases and second primary cancer (SPC) in patients with untreated oropharyngeal or hypopharyngeal squamous cell carcinoma (OHSCC).

Methods

A total of 103 patients were enrolled. All participants underwent 3.0-T WB-MRI and 18F-FDG PET/CT. The diagnostic capabilities of the two imaging modalities were compared using the area under the receiver-operating-characteristic curve. Histology and follow-up data were used as the reference standard.

Results

Of the 103 patients, 18 (17.5%) were found to have either distant metastases or SPC. A total of 21 sites were involved. On a lesion-based analysis, 18F-FDG PET/CT showed a trend toward a higher sensitivity than WB-MRI (81.0% vs. 61.9%, P = 0.125). The area under the curve (AUC) for PET/CT was also higher than for WB-MRI, although not significantly so (0.932 vs. 0.866, P = 0.189). On a patient-based analysis, the sensitivity of WB-MRI was lower than that of PET/CT (66.7% vs. 83.3%, P = 0.625). In terms of diagnostic capability, the AUC was higher for PET/CT than WB-MRI (0.886 vs. 0.813, P = 0.355). The maximal SUV of the regional lymph nodes (SUVn) above the median value (8.7 g/ml) was significantly associated with the occurrence of distant metastasis (P = 0.026).

Conclusion

18F-FDG PET/CT showed a consistent trend toward higher sensitivity and diagnostic capability than 3.0-Tesla WB-MRI for the detection of distant metastases and SPCs in patients with untreated OHSCC. Our data also suggest that SUVn assessed by PET/CT can provide additional information for the prediction of distant metastases
Literature
1.
Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol. 2001;19:1358–62.PubMed
2.
Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202–7.PubMedCrossRef
3.
Goodwin WJ. Distant metastases from oropharyngeal cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:222–3.PubMedCrossRef
4.
Brochet F, Bairati I, Roy J, Gelinas M, Nabid A, Tetu B, et al. Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer. Bull Cancer Radiother. 1996;83:8–11.PubMed
5.
Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV, et al. Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer. 2008;123:2390–6.PubMedCrossRef
6.
Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks Jr WL. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg. 2009;17:88–94.PubMedCrossRef
7.
Lin DT, Cohen SM, Coppit GL, Burkey BB. Squamous cell carcinoma of the oropharynx and hypopharynx. Otolaryngol Clin North Am. 2005;38:59–74.PubMedCrossRef
8.
Brouwer J, Senft A, de Bree R, Comans EF, Golding RP, Castelijns JA, et al. Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol. 2006;42:275–80.PubMedCrossRef
9.
Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180–97.PubMedCrossRef
10.
11.
Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139–48.PubMedCrossRef
12.
Schick F, Whole-body MRI. at high field: technical limits and clinical potential. Eur Radiol. 2005;15:946–59.PubMedCrossRef
13.
Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications, and future applications. Semin Musculoskelet Radiol. 2001;5:5–20.PubMedCrossRef
14.
Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol. 2005;185:711–6.PubMedCrossRef
15.
Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging. 2007;26:498–509.PubMedCrossRef
16.
Squillaci E, Manenti G, Mancino S, Ciccio C, Calabria F, Danieli R, et al. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT – initial clinical experience. Abdom Imaging. 2008;33:676–88.PubMedCrossRef
17.
Lo GG, Ai V, Au-Yeung KM, Chan JK, Li KW, Chien D. Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J. 2008;14:90–6.PubMed
18.
Schmidt GP, Wintersperger B, Graser A, Baur-Melnyk A, Reiser MF, Schoenberg SO. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol. 2007;42:449–59.PubMedCrossRef
19.
20.
Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199–206.PubMedCrossRef
21.
Ng SH, Chan SC, Yen TC, Chang JT, Liao CT, Ko SF, et al. (2009) Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965–76PubMedCrossRef
22.
Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43:557–64.PubMedCrossRef
23.
Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632–42.PubMedCrossRef
24.
Ng SH, Chan SC, Liao CT, Chang JT, Ko SF, Wang HM, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969–79.PubMedCrossRef
25.
Ng SH, Yen TC, Chang JT, Chan SC, Ko SF, Wang HM, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24:4371–6.PubMedCrossRef
26.
Yeh DW, Lee KS, Han J, Yi CA, Lee HY, Chung MJ, et al. Mediastinal nodes in patients with non-small cell lung cancer: MRI findings with PET/CT and pathologic correlation. AJR Am J Roentgenol. 2009;193:813–21.PubMedCrossRef
27.
Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190–5.PubMedCrossRef
28.
Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136–43.PubMed
29.
Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009;19:634–42.PubMedCrossRef
30.
Xu GZ, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head Neck. 2011;33:87–94PubMedCrossRef
31.
Haerle SK, Strobel K, Hany TF, Sidler D, Stoeckli SJ. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck. 2010;32:319–25.PubMed
32.
Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1199–205.PubMedCrossRef
33.
Lauenstein TC, Goehde SC, Herborn CU, Treder W, Ruehm SG, Debatin JF, et al. Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR Am J Roentgenol. 2002;179:445–9.PubMed
34.
Frericks BB, Meyer BC, Martus P, Wendt M, Wolf KJ, Wacker F. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging. 2008;27:538–45.PubMedCrossRef
35.
Devaraj A, Cook GJ, Hansell DM. PET/CT in non-small cell lung cancer staging – promises and problems. Clin Radiol. 2007;62:97–108.PubMedCrossRef
36.
Bakheet SM, Amin T, Alia AG, Kuzo R, Powe J. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med. 1999;24:995–7.PubMedCrossRef
37.
Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.PubMedCrossRef
38.
Chan SC, Chang JT, Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol. 2009;45:52–8.PubMedCrossRef
39.
Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79:747–55PubMedCrossRef
40.
Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;73:764–71.PubMedCrossRef
41.
Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–84.PubMedCrossRef
42.
Jaffe TA, Yoshizumi TT, Toncheva G, Anderson-Evans C, Lowry C, Miller CM, et al. Radiation dose for body CT protocols: variability of scanners at one institution. AJR Am J Roentgenol. 2009;193:1141–7.PubMedCrossRef
43.
Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosim. 2010;139:208–13.CrossRef
Metadata
Title
18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study
Authors
Sheng-Chieh Chan
Hung-Ming Wang
Tzu-Chen Yen
Chien-Yu Lin
Shy-Chyi Chin
Chun-Ta Liao
Yau-Yau Wai
Jiun-Jie Wang
Shu-Hang Ng
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1824-y

Other articles of this Issue 9/2011

European Journal of Nuclear Medicine and Molecular Imaging 9/2011 Go to the issue

Editorial

What we have learned from Fukushima

Original Article

Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer

Original Article

123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma

Original Article

Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours

Letter to the Editor

Is bone marrow uptake of 86Y-DOTATOC routinely observed?

Image of the Month

Lymphoscintigraphy and SPECT/CT using 99mTc filtered sulphur colloid in chylothorax